Navigation Links
Takeda and UCL to work together to tackle muscle disorders
Date:3/9/2014

Japanese pharmaceutical company Takeda will work with University College London (UCL) to drive research into tackling muscle disorders, in particular muscular dystrophy.

The research which is being conducted by the research group of Dr Francesco Saverio Tedesco is being supported through funding of $250,000 from the company's New Frontier Sciences group. Takeda's NFS aims to support innovative, cutting-edge research which could eventually lead to drug discovery and development.

Dr Tedesco's team will focus on the study of muscular regeneration and the potential for stem cell therapies to treat muscular dystrophy, in particular induced pluripotent (iPS) stem cells.

The team is also investigating the potential for treating muscular dystrophy through developing novel gene and cell therapy strategies using artificial human chromosomes and novel biomaterials.

Using this approach, Dr Tedesco hopes to overcome a number of current limitations to developing effective treatments for muscular dystrophies. It is hoped that through the use of these modified stem cells, large quantities of progenitor cells could be produced to be transplanted into a patient's muscle following genetic correction or to be used for drug development platforms.

Importantly, the team will attempt to produce these cells which can be applied more easily in a clinical context, in order to reduce the hurdles that might limit their possible future use in clinical studies.

Through previous work using a mouse model of Duchenne muscular dystrophy, the team has already demonstrated the potential of pre-clinical gene replacement therapy using an artificial human chromosome.

Moreover, in a separate study, Dr Tedesco and his team also demonstrated the potential of genetically corrected iPS cells which had been transplanted into another mouse model of a genetic muscle disorder (limb-girdle muscular dystrophy 2D).

Commenting on the new funding for his research, Dr Tedesco, from the UCL Department of Cell and Developmental Biology, said:

"This funding from Takeda comes at a crucial time for building on our research to develop new and innovative approaches to developing potentially life-changing treatments for muscular dystrophies.

"With Takeda's backing, my team and I will be building on the processes we've already shown to be promising and which could pave the way for the development of novel strategies for both cell therapies and drug discovery in muscle disorders."

Gordon Wong, D.Phil., Head of New Frontier Science at Takeda, added:

"We are delighted to support Dr Tedesco and his team because their ground breaking work has the potential for significant patient benefit."

"That several different strands of their research have already borne fruit was strong evidence for us of the translational potential of Dr Tedesco's research for muscular dystrophies."


'/>"/>

Contact: Henry Rummins
h.rummins@ucl.ac.uk
44-207-679-9063
University College London
Source:Eurekalert

Related biology news :

1. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
2. Elsevier and Energy Institute work together to publish Journal of the Energy Institute
3. Stanford researchers discover how brain regions work together, or alone
4. New organization brings together top researchers to sequence the genomes of invertebrates
5. New organization brings together top researchers to sequence genomes of invertebrates
6. First International Bioenergy Conference brings together world-leading experts
7. Bonding together to fight HIV
8. Fraunhofer and Continental come together when the dandelion rubber meets the road
9. PD map: Putting together the pieces of the Parkinsons puzzle
10. Institut Pasteur Korea -- DNDi come together for the fight against neglected diseases
11. Telecoupling pulls pieces of sustainability puzzle together
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology: